• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply.

作者信息

Bergqvist Viktoria, Holmgren Johanna, Klintman Daniel, Marsal Jan

机构信息

Department of Gastroenterology, Skane University Hospital, Lund/Malmö, Sweden.

Section of Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.

出版信息

Aliment Pharmacol Ther. 2022 Jul;56(2):351-352. doi: 10.1111/apt.17073.

DOI:10.1111/apt.17073
PMID:35748834
Abstract
摘要

相似文献

1
Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply.社论：维多珠单抗从静脉注射无缝转换为皮下注射！作者回复。
Aliment Pharmacol Ther. 2022 Jul;56(2):351-352. doi: 10.1111/apt.17073.
2
Editorial: intravenous to subcutaneous vedolizumab-switch without glitch!社论：从静脉注射维多珠单抗无缝转换为皮下注射！
Aliment Pharmacol Ther. 2022 Jul;56(2):349-350. doi: 10.1111/apt.16989.
3
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.信函：炎症性肠病患者从皮下注射维多珠单抗转换回静脉注射时的棘手反应——作者回复
Aliment Pharmacol Ther. 2023 Mar;57(6):743-744. doi: 10.1111/apt.17407.
4
Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab.换回静脉注射维多珠单抗后，原皮下注射部位出现复发性皮肤反应。
Gastroenterol Hepatol. 2024 Apr;47(4):377-378. doi: 10.1016/j.gastrohep.2023.06.006. Epub 2023 Jul 1.
5
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.社论：维多珠单抗在炎症性肠病老年和非老年匹配队列患者中的有效性和安全性——IG-IBD LIVE研究。作者回复。
Aliment Pharmacol Ther. 2022 Aug;56(4):733-734. doi: 10.1111/apt.17076.
6
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.在一项溃疡性结肠炎患者的随机试验中，维得利珠单抗皮下制剂的疗效和安全性。
Gastroenterology. 2020 Feb;158(3):562-572.e12. doi: 10.1053/j.gastro.2019.08.027. Epub 2019 Aug 28.
7
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.社论：孕期使用维多珠单抗——肠道选择性对宝宝和妈妈一样有益吗？作者回复。
Aliment Pharmacol Ther. 2017 May;45(9):1284. doi: 10.1111/apt.14054.
8
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.社论：维多珠单抗治疗炎症性肠病——少即是多？作者回复。
Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.
9
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.社论：抗TNF药物与维多珠单抗作为二线治疗药物的比较？平局并不意外——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):642-643. doi: 10.1111/apt.16241.
10
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.皮下注射维得利珠单抗治疗中重度活动期克罗恩病的疗效和安全性：VISIBLE 2 随机试验结果。
J Crohns Colitis. 2022 Jan 28;16(1):27-38. doi: 10.1093/ecco-jcc/jjab133.

引用本文的文献

1
Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.维多珠单抗皮下制剂用于炎症性肠病患者的维持治疗：一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2023 Apr 27;16:17562848231166227. doi: 10.1177/17562848231166227. eCollection 2023.